Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE^® 327 in Lung Infection Pilot Study

Recce Pharmaceuticals, Ltd.announced positive results from a preclinical pilot study evaluating nebulized RECCE® 327 for the treatment of lung infections in a mouse model.